Skip to main content
Premium Trial:

Request an Annual Quote

Pressure BioSciences Expects $623K Tax Refund under ARRA

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that it expects to file for a refund of taxes paid for the 2004 calendar year, which would provide the company with $623,000 in the first quarter of 2009.

The South Easton, Mass.-based firm said that under the recently enacted American Recovery and Reinvestment Act, small businesses are eligible to claim the five-year carry back of 2008 net operating losses. Pressure Bio said that it expects to for the refund within the next 90 days.

The company noted that it recently completed a private placement that brought in net proceeds of around $1.8 million. With the extra funds from the tax refund, pressure Bio said that its total stockholders' equity as of Feb. 28, is more than $3.5 million.

"Because of the additional funds that will soon be available to us through the ARRA NOL provision, we have recently re-hired two former employees who were released last November as part of the company's announced restructuring plan, one of whom is full time and the other is part time," Pressure Bio President and CEO Richard Schumacher said in a statement. "These two employees fill vacant but extremely important positions; having them back will help ensure that we meet, or perhaps even beat, our June 30th PCT-enhanced [Protein Digestion System] product release date.''

In December, Pressure Bio undertook a restructuring program, which included cutting eight staffers and closing its R&D facility in Rockville, Md.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.